Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Tuberous Sclerosis × Urination × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Prostatic Neoplasms 3 Lung Neoplasms 2 Disease 2 Colorectal Neoplasms 2 Acute Kidney Injury 2 Urinary Bladder Neoplasms 1 Tuberous Sclerosis 1 Smoldering Multiple Myeloma 1 Salivary Gland Adenoma, Pleomorphic 1 Renal Insufficiency 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphangioleiomyomatosis 1 Kidney Neoplasms 1 Hemangiosarcoma 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Sirolimus 12 Everolimus 10 Activator Appliances 3 Vigabatrin 2 carbon-11 acetate 1 Urination 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Simvastatin 1 Sertraline 1 Selective Serotonin Reuptake Inhibitors 1 Propranolol 1 Phlebotomy 1 Genetic Testing 1 Fluid Therapy 1 Doxycycline 1 Curcumin 1 Calcitriol 1 Aspirin 1 Anticonvulsants 1 Actigraphy 1 Acceptance and Commitment Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05323370 2023-03-29

LAM-CAK

University Hospital, Tours

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡